` CONCORDBIO (Concord Biotech Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

CONCORDBIO
vs
BSE Sensex 30

Over the past 12 months, CONCORDBIO has underperformed BSE Sensex 30, delivering a return of -4% compared to the BSE Sensex 30's 6% growth.

Stocks Performance
CONCORDBIO vs BSE Sensex 30

Loading

Performance Gap
CONCORDBIO vs BSE Sensex 30

Loading
CONCORDBIO
BSE Sensex 30
Difference

Performance By Year
CONCORDBIO vs BSE Sensex 30

Loading
CONCORDBIO
BSE Sensex 30
Add Stock

Competitors Performance
Concord Biotech Ltd vs Peers

BSE Sensex 30
CONCORDBIO
LLY
JNJ
NOVO B
ROG
Add Stock

Concord Biotech Ltd
Glance View

Market Cap
166.1B INR
Industry
Pharmaceuticals

Nestled in the vibrant landscape of the Indian pharmaceutical industry, Concord Biotech Ltd. has woven itself into the intricate fabric of global healthcare solutions. Founded in 2000, the company has carved a niche for itself by becoming a leading manufacturer of fermentation-based biopharmaceutical APIs (Active Pharmaceutical Ingredients). Its core strength lies in developing recombinant APIs and fermentation-based life-saving drugs, establishing a robust pipeline that caters to the therapeutic needs of oncology, immunology, and infectious diseases. Concord Biotech's state-of-the-art manufacturing facilities adhere to stringent international standards, including approvals from USFDA and EUGMP, enabling the company to establish a significant presence in markets across the globe. The company's revenue model thrives on the optimized production of high-demand biotech APIs, synergizing innovation with commercial viability. By partnering with global pharmaceutical giants, Concord Biotech boosts the formulation and development of finished dosage forms, leveraging its cutting-edge research and development capabilities. The firm taps into economies of scale via partnerships and strategic alliances, which allow it to competitively price its offerings while maintaining robust profit margins. Moreover, the company continually invests in expanding its product portfolio and production capacities, ensuring sustainable growth and a strong market position in the ever-evolving pharmaceutical landscape. Through a combination of technological prowess and market insight, Concord Biotech Ltd. paves its path as a cornerstone in the global pharmaceutical supply chain.

CONCORDBIO Intrinsic Value
985.29 INR
Overvaluation 38%
Intrinsic Value
Price
C
Back to Top